A care team, not a comment thread.

Nouri is an independent editorial site. We do not prescribe, dispense, or sell medication; we compare licensed GLP-1 providers and their published prices, and may earn a commission. This archived page covers what to ask about clinician support when you compare providers.

Nouri no longer offers its own GLP-1 program. Compare current options: cheapest GLP-1 prices, best compounded GLP-1 providers, or GLP-1 dose calculators.

Compounded GLP-1s are not FDA-approved. Safety info →

Nouri no longer offers its own GLP-1 program. Compare current options: cheapest GLP-1 prices, best compounded GLP-1 providers, or GLP-1 dose calculators.

Compounded semaglutide is not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs. Compounded medications are prepared based on a prescription from a licensed provider for a specific patient.

GLP-1 medications require a prescription after a medical evaluation by a licensed healthcare provider. Not all patients are eligible. Treatment decisions are made by licensed providers based on individual medical history.

Important Safety Information
What the research shows

The science is real.

15–20%

average body-weight reduction in clinical trials of the branded GLP-1 medications semaglutide and tirzepatide — achieved alongside a structured nutrition and movement plan.

Start Average trajectory in clinical studies · STEP 1 / SURMOUNT‑1, with diet & exercise ~14–17 mo
Questions

Switching, care, and billing: common questions

I’m already on a GLP-1 with another provider. Can I switch?
Usually, yes. Nouri no longer offers its own GLP-1 program. If you switch providers, give the new prescriber your current medication, dose, and history so they can plan your start from where you are — not from zero. Not everyone qualifies.
Are telehealth clinicians real people?
Nouri no longer offers its own GLP-1 program or clinician messaging. When you compare providers, ask whether U.S.-licensed clinicians answer your messages and whether messaging is included in the price.
How does the billing work?
Nouri no longer offers its own GLP-1 program, so there is no Nouri subscription or refund term. Check each provider’s own billing, cancellation and refund policy before you join.
What is included in a GLP-1 program?
Nouri no longer offers its own GLP-1 program. What a provider’s price covers varies, so ask whether it includes the medication, clinician messaging, dose changes, and nutrition guidance. Compare current options in our cheapest GLP-1 cost comparison, our guide to the best compounded GLP-1 providers, or our GLP-1 dose calculators.
What happens if side effects hit at week two?
Message your prescriber — they can adjust your titration. Nausea, vomiting, diarrhea, and constipation are the most common GLP-1 side effects and usually ease as the dose is increased gradually. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not take GLP-1s.
How much does GLP-1 treatment cost?
Nouri no longer offers its own GLP-1 program. Prices vary by provider and medication; compare current options in our cheapest GLP-1 cost comparison or our guide to the best compounded GLP-1 providers.
Are compounded GLP-1s FDA-approved?
No. Compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or manufacturing quality. They are prepared by a licensed 503A compounding pharmacy against an individual prescription, which is permitted under federal law. They are not equivalent to the FDA-approved brand-name drugs Wegovy, Ozempic, Zepbound, or Mounjaro.

Medically reviewed by Amber Patel, MD · Last reviewed June 30, 2026

References

  1. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038